MA28778B1 - Compositions de risedronate et procede d'utilisation de celle-ci - Google Patents

Compositions de risedronate et procede d'utilisation de celle-ci

Info

Publication number
MA28778B1
MA28778B1 MA29645A MA29645A MA28778B1 MA 28778 B1 MA28778 B1 MA 28778B1 MA 29645 A MA29645 A MA 29645A MA 29645 A MA29645 A MA 29645A MA 28778 B1 MA28778 B1 MA 28778B1
Authority
MA
Morocco
Prior art keywords
risedronate
compositions
polymorph
solvate
orally
Prior art date
Application number
MA29645A
Other languages
English (en)
Inventor
David Ernest Burgio Jr
Pamela Jean Schofield
Maurice Kent Gately
Jun Shi
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34958880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28778(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA28778B1 publication Critical patent/MA28778B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention a pour objet un procédé comprenant l'administration par voie orale, à un être humain ou à un autre mammifère, d'une composition pharmaceutique comprenant entre environ 65 % et environ 110 % de la dose efficace accumulée de risédronate ou d'un acide, d'un sel, d'un ester, d'un solvate ou d'un polymorphe de qualité pharmaceutique, suivant un programme de dosage en continu sur un, deux ou trois jours consécutifs par mois, utile pour le traitement ou la prévention de l'ostéoporose et des autres troubles métaboliques osseux.
MA29645A 2004-07-23 2007-02-01 Compositions de risedronate et procede d'utilisation de celle-ci MA28778B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/897,897 US20050070504A1 (en) 2001-12-21 2004-07-23 Risedronate compositions and their methods of use

Publications (1)

Publication Number Publication Date
MA28778B1 true MA28778B1 (fr) 2007-08-01

Family

ID=34958880

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29645A MA28778B1 (fr) 2004-07-23 2007-02-01 Compositions de risedronate et procede d'utilisation de celle-ci

Country Status (20)

Country Link
US (1) US20050070504A1 (fr)
EP (1) EP1776123A1 (fr)
JP (3) JP5377852B2 (fr)
KR (2) KR20070038115A (fr)
CN (1) CN101146542A (fr)
AR (1) AR046036A1 (fr)
AU (2) AU2004322703B2 (fr)
BR (1) BRPI0418973A (fr)
CA (1) CA2564898A1 (fr)
IL (1) IL180907A0 (fr)
IS (1) IS8597A (fr)
MA (1) MA28778B1 (fr)
MX (1) MX2007000967A (fr)
NO (1) NO20071058L (fr)
NZ (1) NZ552799A (fr)
PE (1) PE20060144A1 (fr)
RU (1) RU2007103306A (fr)
TW (1) TWI351286B (fr)
WO (1) WO2006022755A1 (fr)
ZA (1) ZA200701308B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0402267A3 (en) * 2001-12-21 2007-05-29 Procter & Gamble Method for treatment of bone disorders
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
ES2530791T3 (es) * 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
AU2011218625B2 (en) * 2004-05-24 2014-03-20 Theramex HQ UK Limited Dosage forms of risedronate
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US7473684B2 (en) * 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
US20070122477A1 (en) * 2005-10-12 2007-05-31 Cytochroma, Inc. Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
WO2010014766A1 (fr) * 2008-07-31 2010-02-04 Warner Chilcott Company, Llc Faibles formes pharmaceutiques de risédronate ou de ses sels
KR101379664B1 (ko) * 2008-09-23 2014-04-02 한림제약(주) 리세드론산 또는 그의 염 및 비타민 ｄ를 포함하는 약학 조성물
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
PT106978A (pt) * 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CA1339805C (fr) * 1988-01-20 1998-04-07 Yasuo Isomura Acide (cycloalkylamino) methylenebis phosphonique et medicaments le contenant comme ingredients actif
CA1336328C (fr) * 1988-04-11 1995-07-18 Walter G. Leonard Methode pour augmenter la densite osseuse chez l'etre humain
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
NZ253631A (en) * 1992-06-30 1997-02-24 Procter & Gamble Pharma Phosphonate or nsaid pharmaceutical compositions for treating arthritis
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US6750216B2 (en) * 1996-03-08 2004-06-15 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5730715A (en) * 1996-06-14 1998-03-24 Becton Dickinson And Company Method for the iontophoretic administration of bisphosphonates
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
PL337813A1 (en) * 1997-06-11 2000-09-11 Procter & Gamble Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6331533B1 (en) * 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6225801B1 (en) * 1999-01-14 2001-05-01 Lucent Technologies Inc. Article comprising electronic circuits and devices with magnetically programmable electrical resistance
JP2001253827A (ja) * 2000-02-15 2001-09-18 Pfizer Prod Inc 骨粗鬆症を治療するための組成物および方法
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
DK1296689T3 (da) * 2000-06-20 2005-11-28 Novartis Ag Fremgangsmåde til indgivelse af bisphosphonater
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
JP2005516928A (ja) * 2001-12-13 2005-06-09 メルク　エンド　カムパニー　インコーポレーテッド 骨異常のためのビスホスホネート液体製剤
BR0308901A (pt) * 2002-05-10 2005-01-04 Hoffmann La Roche ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
JP5761274B2 (ja) 2015-08-12
JP2008507513A (ja) 2008-03-13
EP1776123A1 (fr) 2007-04-25
KR20070038115A (ko) 2007-04-09
NO20071058L (no) 2007-02-22
JP5377852B2 (ja) 2013-12-25
TWI351286B (en) 2011-11-01
AU2004322703B2 (en) 2010-12-02
AU2004322703A1 (en) 2006-03-02
RU2007103306A (ru) 2008-09-10
JP5910698B2 (ja) 2016-04-27
AU2011200905A1 (en) 2011-03-24
JP2013231087A (ja) 2013-11-14
KR20080083219A (ko) 2008-09-16
NZ552799A (en) 2010-04-30
BRPI0418973A (pt) 2007-12-04
PE20060144A1 (es) 2006-04-17
IL180907A0 (en) 2007-07-04
WO2006022755A1 (fr) 2006-03-02
US20050070504A1 (en) 2005-03-31
AR046036A1 (es) 2005-11-23
TW200603816A (en) 2006-02-01
CA2564898A1 (fr) 2006-03-02
IS8597A (is) 2007-01-24
ZA200701308B (en) 2008-07-30
JP2015038135A (ja) 2015-02-26
MX2007000967A (es) 2007-07-11
CN101146542A (zh) 2008-03-19

Similar Documents

Publication Publication Date Title
TW200744673A (en) Improved ibandronate formulations
EP1848270A4 (fr) Administration par voie transmuqueuse de compositions medicamenteuses pour le traitement et la prevention de troubles chez les animaux
NO20071058L (no) Risedronatsammensetninger og deres fremgangsmater for anvendelse
MA34474B1 (fr) Agonistes de gpr40
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
HRP20120147T1 (hr) Titracija tapentadola
TNSN99223A1 (fr) Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et procedes de traitement les utilisant
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
LU92275I2 (fr) 4-Aminopyridine ou un dérivé de celui-ci, spécialement un sel, un solvant ou une prodrogue
BR0008060A (pt) Composições inibidoras de ciclooxigenase-2 tendo rápido inìcio de eficácia terapêutica
NZ527408A (en) Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
ES2168471T3 (es) 2-(5h)-furanonas diaril-5-oxigenadas como inhibidores de la cox-2.
MA29684B1 (fr) Composes de spiro-oxindole et utilisations associees en tant qu'agents therapeutiques
MA37850A1 (fr) Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
JP2015038135A5 (fr)
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
EA201490277A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA30413B1 (fr) Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation
TNSN04045A1 (fr) Compositions de valdecoxib a delitement intra-oral
MA33463B1 (fr) Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique
MA52154B1 (fr) Composition pharmaceutique pour l'anémie
AU2001277904B2 (en) Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
CA2529604A1 (fr) Compositions pharmaceutiques a dosage oral comprenant un agent d'apport sous forme micronisee
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation